WO2009063202A3 - Use of crth2 antagonist compounds - Google Patents

Use of crth2 antagonist compounds Download PDF

Info

Publication number
WO2009063202A3
WO2009063202A3 PCT/GB2008/003824 GB2008003824W WO2009063202A3 WO 2009063202 A3 WO2009063202 A3 WO 2009063202A3 GB 2008003824 W GB2008003824 W GB 2008003824W WO 2009063202 A3 WO2009063202 A3 WO 2009063202A3
Authority
WO
WIPO (PCT)
Prior art keywords
antagonist compounds
crth2 antagonist
administered
patient
compound
Prior art date
Application number
PCT/GB2008/003824
Other languages
French (fr)
Other versions
WO2009063202A2 (en
Inventor
Michael George Hunter
Eric Roy Pettipher
Colin Michael Perkins
Mark Anthony Payton
Luzheng Xue
Original Assignee
Oxagen Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxagen Limited filed Critical Oxagen Limited
Priority to JP2010532660A priority Critical patent/JP2011503045A/en
Priority to DE08851028T priority patent/DE08851028T1/en
Priority to EP08851028A priority patent/EP2219645A2/en
Publication of WO2009063202A2 publication Critical patent/WO2009063202A2/en
Publication of WO2009063202A3 publication Critical patent/WO2009063202A3/en
Priority to US12/779,638 priority patent/US20110124683A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

The invention relates to compounds of general formula (I) wherein R1, R2, R3, R4 and R5 are as defined herein for the treatment of allergic conditions, wherein the treatment is by pulsed therapy which comprises a first period during which the compound is administered to the patient and a second period of at least seven days during which the compound is administered to the patient in a reduced amount.
PCT/GB2008/003824 2007-11-13 2008-11-13 Use of crth2 antagonist compounds WO2009063202A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2010532660A JP2011503045A (en) 2007-11-13 2008-11-13 Use of CRTH2 antagonistic compounds
DE08851028T DE08851028T1 (en) 2007-11-13 2008-11-13 USE OF CRTH2 ANTAGONIST COMPOUNDS
EP08851028A EP2219645A2 (en) 2007-11-13 2008-11-13 Use of crth2 antagonist compounds
US12/779,638 US20110124683A1 (en) 2007-11-13 2010-05-13 Use of CRTH2 Antagonist Compounds

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0722203.7 2007-11-13
GBGB0722203.7A GB0722203D0 (en) 2007-11-13 2007-11-13 Use of CRTH2 antagonist compounds

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2008/003843 Continuation-In-Part WO2009063215A2 (en) 2007-11-13 2008-11-13 Use of crth2 antagonist compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/779,638 Continuation-In-Part US20110124683A1 (en) 2007-11-13 2010-05-13 Use of CRTH2 Antagonist Compounds

Publications (2)

Publication Number Publication Date
WO2009063202A2 WO2009063202A2 (en) 2009-05-22
WO2009063202A3 true WO2009063202A3 (en) 2009-08-27

Family

ID=38858584

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2008/003824 WO2009063202A2 (en) 2007-11-13 2008-11-13 Use of crth2 antagonist compounds

Country Status (6)

Country Link
EP (1) EP2219645A2 (en)
JP (1) JP2011503045A (en)
DE (1) DE08851028T1 (en)
ES (1) ES2353055T1 (en)
GB (1) GB0722203D0 (en)
WO (1) WO2009063202A2 (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2327693E (en) * 2007-12-14 2012-07-24 Pulmagen Therapeutics Asthma Ltd Indoles and their therapeutic use
WO2009090414A1 (en) * 2008-01-18 2009-07-23 Oxagen Limited Compounds having crth2 antagonist activity
US7750027B2 (en) 2008-01-18 2010-07-06 Oxagen Limited Compounds having CRTH2 antagonist activity
JP2011509990A (en) * 2008-01-22 2011-03-31 オキサジェン リミテッド Compound having CRTH2 antagonist activity
EP2240444A1 (en) * 2008-01-22 2010-10-20 Oxagen Limited Compounds having crth2 antagonist activity
BRPI0907364A2 (en) 2008-02-01 2015-07-14 Amira Pharmaceuticals Inc N, n-disubstituted aminoalkylbiphenyl prostaglandin d2 receptor antagonists
JP2011512359A (en) 2008-02-14 2011-04-21 アミラ ファーマシューティカルズ，インク． Cyclic diaryl ether compounds as antagonists of prostaglandin D2 receptors
US8426449B2 (en) 2008-04-02 2013-04-23 Panmira Pharmaceuticals, Llc Aminoalkylphenyl antagonists of prostaglandin D2 receptors
WO2010008864A2 (en) 2008-06-24 2010-01-21 Amira Pharmaceuticals, Inc. Cycloalkane[b]indole angtagonists of prostaglandin d2 receptors
CN102076661B (en) 2008-07-03 2014-04-09 潘米拉制药公司 Antagonists of prostaglandin d2 receptors
GB2463788B (en) 2008-09-29 2010-12-15 Amira Pharmaceuticals Inc Heteroaryl antagonists of prostaglandin D2 receptors
GB2465062B (en) 2008-11-06 2011-04-13 Amira Pharmaceuticals Inc Cycloalkane(B)azaindole antagonists of prostaglandin D2 receptors
US8383654B2 (en) 2008-11-17 2013-02-26 Panmira Pharmaceuticals, Llc Heterocyclic antagonists of prostaglandin D2 receptors
EP2461809A4 (en) 2009-07-31 2013-06-19 Panmira Pharmaceuticals Llc Ophthalmic pharmaceutical compositions of dp2 receptor antagonists
SG10201404662YA (en) 2009-08-05 2014-10-30 Panmira Pharmaceuticals Llc Dp2 antagonist and uses thereof
KR20120115989A (en) 2010-01-06 2012-10-19 판미라 파마슈티칼스, 엘엘씨 Dp2 antagonist and uses thereof
KR101444572B1 (en) 2010-03-22 2014-09-24 액테리온 파마슈티칼 리미티드 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazole derivatives and their use as prostaglandin d2 receptor modulators
JP5952829B2 (en) * 2010-12-23 2016-07-13 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Quinoxalines and aza-quinoxalines as CRTH2 receptor modulators
GB201103837D0 (en) 2011-03-07 2011-04-20 Oxagen Ltd Amorphous (5-Fluoro-2-Methyl-3-Quinolin-2-Ylmethyl-Indol-1-Yl)-acetic acid
ES2596581T3 (en) 2011-04-14 2017-01-10 Actelion Pharmaceuticals Ltd. Derivatives of 7- (heteroaryl-amino) -6,7,8,9-tetrahydropyridido [1,2-a] indole acetic acid and its use as modulators of the prostaglandin D2 receptor
CN103086943B (en) * 2011-11-04 2015-04-15 山东亨利医药科技有限责任公司 Indoles derivative functioning as CRTH2 receptor antagonist
MY179356A (en) 2014-03-17 2020-11-05 Idorsia Pharmaceuticals Ltd Azaindole acetic acid derivatives and their use as prostaglandin d2 receptor modulators
CA2938107A1 (en) 2014-03-18 2015-09-24 Actelion Pharmaceuticals Ltd Azaindole acetic acid derivatives and their use as prostaglandin d2 receptor modulators
GB201407820D0 (en) 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form
GB201407807D0 (en) 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form
TWI711616B (en) 2015-09-15 2020-12-01 瑞士商愛杜西亞製藥有限公司 Crystalline forms
JPWO2017104728A1 (en) * 2015-12-16 2018-11-29 幸久 村田 Food allergy medicine
EP3489233B1 (en) * 2016-07-21 2022-01-12 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Indole derivative used as crth2 inhibitor

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005044260A1 (en) * 2003-10-23 2005-05-19 Oxagen Limited Use of crth2 antagonist compounds in therapy
WO2006092579A1 (en) * 2005-03-01 2006-09-08 Oxagen Limited Microcrystalline ( 5-fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl) acetic acid
WO2006095183A1 (en) * 2005-03-11 2006-09-14 Oxagen Limited 1-acetic acid-indole derivatives with pgd2 antagonist activity
WO2007107772A1 (en) * 2006-03-22 2007-09-27 Oxagen Limited Salts with crth2 antagonist activity
WO2008012511A1 (en) * 2006-07-22 2008-01-31 Oxagen Limited Compounds having crth2 antagonist activity

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005044260A1 (en) * 2003-10-23 2005-05-19 Oxagen Limited Use of crth2 antagonist compounds in therapy
WO2006092579A1 (en) * 2005-03-01 2006-09-08 Oxagen Limited Microcrystalline ( 5-fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl) acetic acid
WO2006095183A1 (en) * 2005-03-11 2006-09-14 Oxagen Limited 1-acetic acid-indole derivatives with pgd2 antagonist activity
WO2007107772A1 (en) * 2006-03-22 2007-09-27 Oxagen Limited Salts with crth2 antagonist activity
WO2008012511A1 (en) * 2006-07-22 2008-01-31 Oxagen Limited Compounds having crth2 antagonist activity

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "View of NCT00290381 on 2006_02_10", CLINICALTRIALS.GOV ARCHIVE, 10 February 2006 (2006-02-10), XP002534990, Retrieved from the Internet <URL:http://clinicaltrials.gov/archive/NCT00290381/2006_02_10> *
ANONYMOUS: "View of NCT00697281 on 2008_06_12", CLINICAL TRIALS.GOV ARCHIVE, 12 June 2008 (2008-06-12), XP002535051, Retrieved from the Internet <URL:http://clinicaltrials.gov/archive/NCT00697281/2008_06_12> *
See also references of EP2219645A2 *

Also Published As

Publication number Publication date
WO2009063202A2 (en) 2009-05-22
DE08851028T1 (en) 2011-02-24
GB0722203D0 (en) 2007-12-19
JP2011503045A (en) 2011-01-27
ES2353055T1 (en) 2011-02-25
EP2219645A2 (en) 2010-08-25

Similar Documents

Publication Publication Date Title
WO2009063202A3 (en) Use of crth2 antagonist compounds
WO2007129195A3 (en) 4-pyrimidine-5-amino-pyrazole compounds
EP1857457A3 (en) Benzimidazole derivative and its use as AII receptor antagonist
WO2006018182A8 (en) Combinations for the treatment of diseases involving cell proliferation
TW200833663A (en) Therapeutic agents
WO2005116002A3 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
WO2005075425A3 (en) Substituted bisarylurea derivatives as kinase inhibitors
WO2008012635A3 (en) Amine derivatives useful as anticancer agents
MX2008002061A (en) Thiazolyl piperidine derivatives.
WO2009120660A3 (en) Substituted pyridoxazines
WO2009155121A3 (en) Inhibitors of pi3 kinase
WO2006067165A3 (en) Indolidone derivatives for the treatment or prevention of fibrotic diseases
WO2010093849A3 (en) Phenylalanine amide derivatives useful for treating insulin-related diseases and conditions
WO2011027249A3 (en) Benzimidazole derivatives
ATE517882T1 (en) QUINOLINE DERIVATIVES
WO2009082819A8 (en) Novel lupane derivatives
WO2007133637A3 (en) Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
MX2010002392A (en) Improved brimonidine compositions for treating erythema.
WO2012116290A3 (en) Neuroactive 17(20)-z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same
WO2007024843A3 (en) Pyrimidinyl-pyrazole inhibitors of aurora kinases
WO2009066041A3 (en) Derivatives of 1,2,4,5-tetrahydro-3h-benzazepines, preparation method therefor and pharmaceutical compositions containing same
NO20083058L (en) Cyclohexylsulfonamide derivatives with H3 receptor activity
EP1627635A3 (en) Benzothiazolium compounds for use in methods of inhibiting NO production and TNF alpha and treating coronaviral infection
WO2007009723A3 (en) Azepane- or azocane-substituted pyrazoline derivatives, their preparation and use as medicaments
MX2009010731A (en) 1-(1-benzylpiperidin-4-yl)benzimidaz0le -5-carboxylic acid derivatives for the treatment of diabetes mellitus.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08851028

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2010532660

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008851028

Country of ref document: EP